Immunodeficiency Disorders and Transplant Immunology

Core Idea

Primary immunodeficiencies affect innate immunity (IRAK4, MyD88 mutations), T cell development (DiGeorge syndrome), B cell development (X-linked agammaglobulinemia), or lymphocyte function (SCID). Secondary immunodeficiencies follow infection (HIV), malignancy, or medications (chemotherapy, corticosteroids). Transplant rejection occurs when donor MHC alloantigens trigger T cell and antibody responses: acute cellular rejection (7-90 days, T cell-mediated), acute humoral rejection (hours-days, alloantibody-mediated), and chronic rejection (months-years, progressive vasculitis). Immunosuppression with calcineurin inhibitors, mTOR inhibitors, and depleting antibodies prolongs graft survival.

How It's Best Learned

Map primary immunodeficiencies to affected immune components (innate, T cell, B cell, lymphocyte function). Compare rejection mechanisms and immunosuppressive strategies.

Common Misconceptions

• Immunodeficiency always causes severe infections (some defects cause specific vulnerabilities, e.g., C3 deficiency predisposes to pneumococcal infection). - Transplant rejection is a single process (acute and chronic rejection use different mechanisms).

Explainer

Immunodeficiency disorders and transplant rejection may seem like opposite problems — too little immunity versus too much — but they are deeply connected through the same principles of adaptive and innate immune function that you have already studied. Understanding immunodeficiency reveals which immune components are essential for which types of defense, while transplant immunology shows what happens when a fully competent immune system encounters foreign tissue that it was never meant to tolerate.

Primary immunodeficiencies are inherited genetic defects that impair specific branches of immunity, and the clinical pattern of infections reveals which branch is compromised. Defects in B cells or antibody production (such as X-linked agammaglobulinemia, caused by mutations in Bruton's tyrosine kinase) result in recurrent bacterial infections of the respiratory and gastrointestinal tracts — the encapsulated bacteria that antibodies and complement normally handle. Defects in T cell development (such as DiGeorge syndrome, caused by thymic aplasia from a 22q11 deletion) lead to susceptibility to viral, fungal, and intracellular bacterial infections — the pathogens that require cell-mediated immunity. Severe combined immunodeficiency (SCID) affects both T and B cell lineages (often through mutations in the common gamma chain of cytokine receptors or in RAG recombinases) and is fatal without intervention because virtually all adaptive immunity is absent. Secondary immunodeficiencies arise from external causes — HIV destroys CD4+ T cells, chemotherapy kills dividing lymphocytes, and corticosteroids suppress immune activation broadly.

Transplant rejection occurs because the adaptive immune system evolved to recognize non-self MHC molecules with extraordinary sensitivity. Donor organs express allogeneic MHC (HLA) molecules that differ from the recipient's, and these foreign MHC molecules are the dominant targets of rejection. Rejection is classified by mechanism and timing. Hyperacute rejection (minutes to hours) occurs when preformed recipient antibodies against donor MHC or ABO antigens activate complement and destroy graft vasculature — this is largely prevented by pre-transplant crossmatching. Acute cellular rejection (days to months) is driven by recipient T cells that recognize donor MHC molecules either directly (T cells bind intact donor MHC on graft antigen-presenting cells) or indirectly (recipient APCs process and present donor MHC peptides). Chronic rejection (months to years) involves a slow, progressive vasculopathy driven by both cellular and humoral mechanisms, leading to graft fibrosis and eventual failure.

Modern transplant medicine relies on immunosuppressive drugs that target the very adaptive immune mechanisms you have studied. Calcineurin inhibitors (cyclosporine, tacrolimus) block the calcium-dependent signaling pathway that activates NFAT and drives T cell IL-2 production — essentially silencing T cell activation at the transcriptional level. mTOR inhibitors (sirolimus) block the proliferation signal downstream of IL-2 receptor engagement. Mycophenolate inhibits purine synthesis required for lymphocyte proliferation. Anti-thymocyte globulin and anti-CD20 antibodies (rituximab) deplete T cells and B cells respectively. The fundamental tradeoff is unavoidable: suppressing rejection creates a state of iatrogenic immunodeficiency, increasing susceptibility to the same opportunistic infections and malignancies seen in primary immunodeficiency. Balancing graft survival against infection risk is the central clinical challenge of transplant medicine.